InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.720 0.005 (0.70%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$196 Technology and Data Presentations at key Ortho Conferences 15 Oct 2015 11:40AM $0.620 $0.720 risen by 16.13%
$196 Orthocell Presents at Stem Cell Meeting on the Mesa 8 Oct 2015 8:24AM $0.650 $0.720 risen by 10.77%
$196 Investor Presentation 23 Sep 2015 8:28AM $0.635 $0.720 risen by 13.39%
$196 Full Year Statutory Accounts 18 Sep 2015 7:07PM $0.650 $0.720 risen by 10.77%
$196 Further Details to Cell Factory Announcement and Update 16 Sep 2015 9:29AM $0.580 $0.720 risen by 24.14%
$196 Orthocells Cell Factory validated for bone regeneration 15 Sep 2015 9:27AM $0.530 $0.720 risen by 35.85%
$196 Preliminary Final Report 28 Aug 2015 6:16PM $0.610 $0.720 risen by 18.03%
$196 Orthocell Holds Inaugural User Group Meeting 11 Aug 2015 10:18AM $0.845 $0.720 fallen by 14.79%
$196 Appendix 4C - quarterly 31 Jul 2015 5:09PM $0.720 $0.720 fallen by 0%
$196 Response to ASX Aware Query 27 Jul 2015 11:38AM $0.860 $0.720 fallen by 16.28%
$196 Release of Securities from Escrow 17 Jul 2015 5:17PM $0.560 $0.720 risen by 28.57%
$196 Pipeline Cartilage Product Validated in Leading Publication 16 Jul 2015 10:15AM $0.465 $0.720 risen by 54.84%
$196 Grant for World First Laboratory Grown Tendon Received 9 Jul 2015 10:01AM $0.380 $0.720 risen by 89.47%
$196 Response to ASX Price Query 6 Jul 2015 1:42PM $0.380 $0.720 risen by 89.47%
$196 Orthocell Receives R&D Tax Incentive Cash Refund 28 May 2015 9:26AM $0.385 $0.720 risen by 87.01%
$196 Orthocell presents at London Regenerative Medicine Congress 25 May 2015 11:46AM $0.380 $0.720 risen by 89.47%
$196 Ortho-ATI Data Presented at Key International Conference 12 May 2015 9:52AM $0.390 $0.720 risen by 84.62%
$196 Release of Shares from Escrow 12 May 2015 9:40AM $0.390 $0.720 risen by 84.62%
$196 Appendix 4C - quarterly 30 Apr 2015 6:17PM $0.405 $0.720 risen by 77.78%
$196 Prestigious Journal Publishes Ortho-ATI Study Findings 30 Apr 2015 8:50AM $0.390 $0.720 risen by 84.62%
$196 Orthocell Receives Approval for Celgro Dental Study 9 Mar 2015 9:58AM n/a $0.720 n/a
$196 Half Yearly Report and Accounts 26 Feb 2015 8:10PM $0.380 $0.720 risen by 89.47%
$196 First Patients in Hong Kong Treated With Ortho-ATI Therapy 9 Feb 2015 9:38AM n/a $0.720 n/a
$196 Appendix 4C - quarterly 30 Jan 2015 6:51PM n/a $0.720 n/a
$196 US Patent Received for CELGRO 29 Jan 2015 12:19PM $0.400 $0.720 risen by 80%

726 - 750 of 759 results

Page 30 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.